ReviewInternational journal of molecular sciences2023
Hormonal Gut-Brain Signaling for the Treatment of Obesity.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.Molecular metabolism · 2026Trial
- Postoperative Changes in Eating Behavior After Sleeve Gastrectomy are Associated With IL-10 Independent of Anthropometric Changes.Obesity surgery · 2026Article
- Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment.Diabetes, obesity & metabolism · 2026Review
- Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.Obesity science & practice · 2026Review
- GCGR agonism requires GABAergic signaling in the medial basal hypothalamus to promote weight loss in obese mice.Molecular metabolism · 2026Article
- Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments.Current HIV/AIDS reports · 2026Review
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- Acupuncture ameliorates diet-induced obesity via the vagal-GLP-1-ARC circuit: neural mechanism of anorexigenic action.Chinese medicine · 2026Article
- Obesity: assessment and treatment across the care continuum.Annals of medicine · 2025Review
- Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document.European journal of heart failure · 2025Review
- Vagal Oxytocin Receptors as Molecular Targets in Gut-Brain Signaling: Implications for Appetite, Satiety, Obesity, and Esophageal Motility-A Narrative Review.International journal of molecular sciences · 2025Review
- Tirzepatide: a novel therapeutic approach for Alzheimer's disease.Metabolic brain disease · 2025Review
- The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Smoking, Obesity, and Post-Cessation Weight Gain: Neurobiological Intersection and Treatment Recommendations.Journal of multidisciplinary healthcare · 2025Review
- GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.Therapeutic advances in endocrinology and metabolism · 2025Review
- The Possible Involvement of Glucagon-like Peptide-2 in the Regulation of Food Intake through the Gut-Brain Axis.Nutrients · 2024Review
- A network frame offers a promising transdisciplinary tool for understanding complex health and health care system problems like suicide.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacology research & perspectives · 2024Review
- Current Approaches to Prevent or Reverse Microbiome Dysbiosis in Chronic Inflammatory Rheumatic Diseases.Mediterranean journal of rheumatology · 2024Review
- Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population.Journal of cardiovascular development and disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The brain, particularly the hypothalamus and brainstem, monitors and integrates circulating metabolic signals, including gut hormones. Gut-brain communication is also mediated by the vagus nerve, which transmits various gut-derived signals. Recent advances in our understanding of molecular gut-brain communication promote the development of next-generation anti-obesity medications that can safely achieve substantial and lasting weight loss comparable to metabolic surgery. Herein, we comprehensively review the current knowledge about the central regulation of energy homeostasis, gut hormones involved in the regulation of food intake, and clinical data on how these hormones have been applied to the development of anti-obesity drugs. Insight into and understanding of the gut-brain axis may provide new therapeutic perspectives for the treatment of obesity and diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.